BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

On May 25, 2017, BioCryst Pharmaceuticals, Inc. (the Company)
announced results from a second interim analysis of its Phase 2
APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 is a
3-part dose ranging trial designed to evaluate the efficacy,
safety, tolerability, pharmacokinetics and pharmacodynamics of
orally administered once-daily BCX7353 for 28 days, as a
preventative treatment to reduce the frequency of attacks in HAE
patients.

On May 25, 2017, the Company issued a news release announcing the
events described in this Item 7.01. A copy of the news release is
furnished as Exhibit 99.1 hereto and is incorporated herein by
reference.

The information furnished in this Item 7.01, including Exhibit
99.1, is not deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, is not subject to
the liabilities of that section and is not deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCrysts actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with
respect to future events and are based on assumptions and are
subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. Some of the factors that could affect the
forward-looking statements contained herein include: that
developing any HAE drug candidate may take longer or may be more
expensive than planned; that ongoing and future preclinical and
clinical development of HAE second generation drug candidates
(including APeX-1 and ZENITH-1) may not have positive results;
that BioCryst may not be able to enroll the required number of
subjects in planned clinical trials of product candidates; that
the Company may not advance human clinical trials with product
candidates as expected; that the FDA may require additional
studies beyond the studies planned for product candidates, or may
not provide regulatory clearances which may result in delay of
planned clinical trials, or may impose a clinical hold with
respect to such product candidate, or withhold market approval
for product candidates; that BioCryst may not receive additional
government funding to further support the development of
galidesivir; that galidesivir development may not be successful;
that BARDA and/or NIAID may further condition, reduce or
eliminate future funding; that revenue from peramivir injection
is unpredictable and may never result in significant revenue for
the Company; that the Company may not be able to continue
development of ongoing and future development programs; that such
development programs may never result in future products; that
actual financial results may not be consistent with expectations,
including that 2017 operating expenses and cash usage may not be
within managements expected ranges. Please refer to the documents
BioCryst files periodically with the Securities and Exchange
Commission, specifically BioCrysts most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, all of which identify important factors that could
cause the actual results to differ materially from those
contained in BioCrysts projections and forward-looking
statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated May 25, 2017 entitled BioCryst Reports
Additional Positive Results from the Second Interim
Analysis of its APeX-1 Trial


About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session down -0.02 at 5.13 with 642,566 shares trading hands.

An ad to help with our costs